Company news

Scholar Rock Holding Corporation (NASDAQ:SRRK) news

Scholar Rock Holding Corporation news releases on 6ix. Latest, Oct 31, 2024: Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON…

Scholar Rock Holding Corporation (NASDAQ:SRRK) news

Press releases — page 2

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

Scholar Rock to Host Investor Day on May 22, 2024

Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting

Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Scholar Rock Announces Proposed Public Offering of Common Stock

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

Scholar Rock to Present at the Jefferies Healthcare Conference

Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting

Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy